Delivery Order SPE2DB22D1017-SPE2DB25FG7YM
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on June 6, 2025, for the supply of Jardiance 10 mg tablets (90-count units) with a ceiling value of $3,462.82. This is a firm fixed price delivery order with an ultimate completion date of June 9, 2025, and represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement...
- The Defense Logistics Agency (DLA) awarded a delivery order contract valued at $12,877.73 to AmerisourceBergen Drug Corp for the supply of Jardiance 10 mg tablets (90-count units) on July 22, 2025, with completion expected by July 23, 2025. This competitively awarded, non-set-aside contract employs firm fixed pricing and identifies AmerisourceBergen's Conshohocken, Pennsylvania facility as the place of performance. The award represents a child delivery order issued under a larger contract...
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on June 18, 2025, for the supply of Jardiance 10 mg tablets (90-count packages) with a contract ceiling value of $18,239.53. This firm fixed-price delivery order, with an ultimate completion date of June 20, 2025, represents a competitive award with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania—the location of performance for...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Jardiance 25 mg tablets (90-count) on July 24, 2025, with a ceiling value of $5,119.23 and an ultimate completion date of July 25, 2025. This firm fixed-price delivery order represents a non-set-aside competitive award and is performed from the vendor's location in Conshohocken, Pennsylvania. The award falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Jardiance 25 mg tablets (90-count) with a contract ceiling value of $31,642.05. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 15, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract represents a routine pharmaceutical procurement supporting federal...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Jardiance 25 mg tablets (90-count units) at a ceiling value of $49,619.13. This firm fixed-price delivery order, with an ultimate completion date of August 14, 2025, represents a competitive award with no set-aside designation and is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Jardiance 25 mg tablets (90-count units) with a ceiling value of $81,786.40. This competitively awarded, firm fixed-price delivery order is set to be completed by September 9, 2025, and will be fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,313.76 to AmerisourceBergen Drug Corp for the supply of Jardiance 25 mg tablets (90-count packages) on September 15, 2025, with an ultimate completion date of September 16, 2025. This firm fixed-price delivery order, which carries no set-aside designation, was awarded competitively and represents a single transaction under AmerisourceBergen's broader pharmaceutical supply relationship with the federal government. The...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,578.75 to AmerisourceBergen Drug Corp for the supply of Jardiance 10 mg tablets (90-count packages) on July 28, 2025, with an ultimate completion date of July 29, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award falls under AmerisourceBergen Drug Corp's existing...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Jardiance 10 mg tablets (90-count units) under a firm fixed-price contract valued at $11,743.92, with an ultimate completion date of July 28, 2025. This non-set-aside competitive award represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, a $999.99 billion prime vendor agreement running through...
- SPE2DB22D1017Indefinite Delivery Contract
- SPE2DB22D1017-SPE2DB25FG7YMDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Jardiance 10 mg tablets in a 90-count package. This is a firm fixed-price delivery order with a ceiling value of $12,387.85 and an ultimate completion date of July 23, 2025. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, and was awarded without a set-aside designation, indicating it was competed among eligible vendors. This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical vendor for federal medical procurement through the DLA's Medical Supply Chain. The company supplies a broad portfolio of pharmaceutical products and medical supplies to support military and veteran healthcare systems, including brand-name and generic medications across multiple therapeutic domains. Jardiance, an antidiabetic medication, aligns with the company's demonstrated capability to deliver specialty pharmaceuticals to federal healthcare programs, including the Defense Health Agency and U.S. Coast Guard, through the DLA's Pharmaceutical Prime Vendor Global Program vehicle.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $12.4k | 7/22/25 |